Oncolytic Virus Cancer Therapy- Pipeline Insights, 2019
This report can be delivered to the clients within 48 hours
'Oncolytic Virus Cancer Therapy- Pipeline Insights, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across Oncolytic Virus Cancer Therapy. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 65+ products with more than 25 companies involved. Some of the emerging products include Pexa-Vec of Transgene/SillaJen, Telomelsin of Oncolys, and Canerpaturev (TBI-1401) of Takara Bio.
Products covered by Phase
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Oncolytic Virus Cancer Therapy
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE OF THE REPORT
'Oncolytic Virus Cancer Therapy- Pipeline Insights, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across Oncolytic Virus Cancer Therapy. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 65+ products with more than 25 companies involved. Some of the emerging products include Pexa-Vec of Transgene/SillaJen, Telomelsin of Oncolys, and Canerpaturev (TBI-1401) of Takara Bio.
Products covered by Phase
- Phase III, Phase II, Phase I
- IND
- Pre-clinical & Discovery
- Inactive
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Oncolytic Virus Cancer Therapy
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE OF THE REPORT
- Provides an overview of therapeutic pipeline activity for Oncolytic Virus Cancer Therapy across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Oncolytic Virus Cancer Therapy therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
- Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
- Coverage of dormant and discontinued pipeline projects across Oncolytic Virus Cancer Therapy
- Establish a comprehensive understanding of the current pipeline scenario across Oncolytic Virus Cancer Therapy to formulate effective R&D strategies
- Assess challenges and opportunities that influence Oncolytic Virus Cancer Therapy R&D
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Oncolytic Virus Cancer Therapy to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive and discontinued drugs
Executive Summary
Overview
Introduction
History of Oncolytic Virus
Mechanism of Action
Criteria of Selection on Oncolytic Virus for Cancer Therapy
Strategies for Tumor Targeting
Types of Cancer Treated
Oncolytic Viruses vs Other Therapies
Side effects of Oncolytic Viral Therapy
Limitations of Oncolytic Viral Therapy
Conclusion and Future Perspectives
Pipeline Therapeutics (Active Products)
Pipeline Therapeutics (Inactive Products)
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Pexa-Vec: Transgene/SillaJen
Product Description
Research and Development
Product Development Activities
The list continues
Mid Stage Products (Phase II)
Comparative Analysis
Telomelsin: Oncolys
Product Description
Research and Development
Product Development Activities
The list continues
Early Stage Products (Phase I & IND)
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Inactive Products
Comparative Analysis
APPENDIX
Overview
Introduction
History of Oncolytic Virus
Mechanism of Action
Criteria of Selection on Oncolytic Virus for Cancer Therapy
Strategies for Tumor Targeting
Types of Cancer Treated
Oncolytic Viruses vs Other Therapies
Side effects of Oncolytic Viral Therapy
Limitations of Oncolytic Viral Therapy
Conclusion and Future Perspectives
Pipeline Therapeutics (Active Products)
Pipeline Therapeutics (Inactive Products)
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Pexa-Vec: Transgene/SillaJen
Product Description
Research and Development
Product Development Activities
The list continues
Mid Stage Products (Phase II)
Comparative Analysis
Telomelsin: Oncolys
Product Description
Research and Development
Product Development Activities
The list continues
Early Stage Products (Phase I & IND)
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Inactive Products
Comparative Analysis
APPENDIX
LIST OF TABLES
List of Tables
Table 1: Total Products for Oncolytic Virus Cancer Therapy
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I & IND)
Table 5: Pre-clinical and Discovery Stage Products
Table 6: Assessment by Stage and Product Type
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Inactive Products
List of Tables
Table 1: Total Products for Oncolytic Virus Cancer Therapy
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I & IND)
Table 5: Pre-clinical and Discovery Stage Products
Table 6: Assessment by Stage and Product Type
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Inactive Products
LIST OF FIGURES
List of Figures
Figure 1: Total Products for Oncolytic Virus Cancer Therapy
Figure 2: Late Stage Products (Phase III)
Figure 3: Mid Stage Products (Phase II)
Figure 4: Early Stage Products (Phase I & IND)
Figure 5: Pre-clinical and Discovery Stage Products
Figure 6: Assessment by Stage and Product Type
Figure 7: Assessment by Route of Administration
Figure 8: Assessment by Stage and Route of Administration
Figure 9: Assessment by Molecule Type
Figure 10: Assessment by Stage and Molecule Type
Figure 11: Inactive Products
KEY COMPANIES
SillaJen
Oryx
PsiOxus Therapeutics
Daiichi Sankyo
Vyriad
Genelux
Takara Bio
DNAtrix
Merck
Oncolytics Biotech
Oncolys BioPharma
Vrittu Biologics limited
Transgene
VCN Biosciences
CZ Biomed
Cell Genesys
Lokon Pharma
List of Figures
Figure 1: Total Products for Oncolytic Virus Cancer Therapy
Figure 2: Late Stage Products (Phase III)
Figure 3: Mid Stage Products (Phase II)
Figure 4: Early Stage Products (Phase I & IND)
Figure 5: Pre-clinical and Discovery Stage Products
Figure 6: Assessment by Stage and Product Type
Figure 7: Assessment by Route of Administration
Figure 8: Assessment by Stage and Route of Administration
Figure 9: Assessment by Molecule Type
Figure 10: Assessment by Stage and Molecule Type
Figure 11: Inactive Products
KEY COMPANIES
SillaJen
Oryx
PsiOxus Therapeutics
Daiichi Sankyo
Vyriad
Genelux
Takara Bio
DNAtrix
Merck
Oncolytics Biotech
Oncolys BioPharma
Vrittu Biologics limited
Transgene
VCN Biosciences
CZ Biomed
Cell Genesys
Lokon Pharma
